Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design

Overview

Journal Kidney Int Rep

Publisher Elsevier

Specialty Nephrology

Date 2021 Oct 8

PMID 34622097

Citations 15

Authors

Liron Walsh

John F Reilly

Caitlin Cornwall

Gregory A Gaich

Debbie S Gipson

Hiddo J L Heerspink

Leslie Johnson

Howard Trachtman

Katherine R Tuttle

Youssef M K Farag

Krishna Padmanabhan

Xin-Ru Pan-Zhou

James R Woodworth

Frank S Czerwiec

Affiliations

Soon will be listed here.

Abstract

Introduction: A critical unmet need exists for precision therapies for chronic kidney disease. GFB-887 is a podocyte-targeting, small molecule inhibitor of transient receptor potential canonical-5 (TRPC5) designed specifically to treat patients with glomerular kidney diseases characterized by an overactivation of the TRPC5-Rac1 pathway. In a first-in-human study, GFB-887 was found to be safe and well tolerated, had a pharmacokinetic (PK) profile allowing once-daily dosing, and dose dependently decreased urinary Rac1 in healthy adults.

Methods: TRACTION-2 is a phase 2a, double-blind, placebo-controlled, multiple-ascending dose study of GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), treatment-resistant minimal change disease (TR-MCD), or diabetic nephropathy (DN) (NCT04387448). Adult patients on stable renin-angiotensin system blockade and/or immunosuppression with persistent proteinuria will be randomized and dosed in 3 ascending dose levels to GFB-887 or placebo for 12 weeks. Cohorts may be expanded or biomarker-enriched depending upon results of an adaptive interim analysis.

Results: The primary objective is to evaluate the effect of increasing doses of GFB-887 on proteinuria. Safety and tolerability, quality of life, pharmacokinetic/pharmacodynamic profiles, and the potential association of urinary Rac1 with efficacy will also be evaluated. The projected sample size has 80% power to detect a treatment difference in proteinuria of 54% (FSGS/TR-MCD) or 44% (DN) compared to placebo.

Conclusion: TRACTION-2 will explore whether targeted blockade of the TRPC5-Rac1 pathway with GFB-887 is an efficacious and safe treatment strategy for patients with FSGS, TR-MCD, and DN and the potential value of urinary Rac1 as a predictive biomarker of treatment response.

Citing Articles

Targeting TRPC-5 Channel Inhibition to Improve Penile Vascular Function in Erectile Dysfunction.

El Assar M, Garcia-Gomez B, La Fuente J, Alonso-Isa M, Martinez-Salamanca J, Fernandez A Int J Mol Sci. 2025; 26(4).

PMID: 40003900 PMC: 11855833. DOI: 10.3390/ijms26041431.

Advances in Focal Segmental Glomerulosclerosis Treatment From the Perspective of the Newest Mechanisms of Podocyte Injury.

Zhu Y, Xu G Drug Des Devel Ther. 2025; 19:857-875.

PMID: 39935575 PMC: 11812565. DOI: 10.2147/DDDT.S498457.

Synthesis and Insecticidal/Fungicidal Activities of Triazone Derivatives Containing Acylhydrazone Moieties.

Cui P, Yang Y Molecules. 2025; 30(2.

PMID: 39860209 PMC: 11767570. DOI: 10.3390/molecules30020340.

Targeting RAC1 might be a potential therapeutic strategy for diabetic kidney disease: a Mendelian randomization study.

Han S, Jia M, Yao T, Xu Y, Wang Y Int Urol Nephrol. 2024; 57(2):625-633.

PMID: 39368040 DOI: 10.1007/s11255-024-04225-z.

Thermosensing ability of TRPC5: current knowledge and unsettled questions.

Ptakova A, Vlachova V J Physiol Sci. 2024; 74(1):50.

PMID: 39363236 PMC: 11447943. DOI: 10.1186/s12576-024-00942-3.

References

Mathias S, Vallow S, Gipson D, Thorneloe K, Sprecher D . Development of Focal Segmental Glomerulosclerosis Patient-Reported Outcome Measures: Symptom Diary and Symptom Impact Questionnaire. Am J Kidney Dis. 2017; 70(4):532-540. DOI: 10.1053/j.ajkd.2017.04.023. View

Waldman M, John Crew R, Valeri A, Busch J, Stokes B, Markowitz G . Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007; 2(3):445-53. DOI: 10.2215/CJN.03531006. View

Gee H, Saisawat P, Ashraf S, Hurd T, Vega-Warner V, Fang H . ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling. J Clin Invest. 2013; 123(8):3243-53. PMC: 3726174. DOI: 10.1172/JCI69134. View

Riccio A, Li Y, Moon J, Kim K, Smith K, Rudolph U . Essential role for TRPC5 in amygdala function and fear-related behavior. Cell. 2009; 137(4):761-72. PMC: 2719954. DOI: 10.1016/j.cell.2009.03.039. View

Lusco M, Fogo A, Najafian B, Alpers C . AJKD Atlas of Renal Pathology: Calcineurin Inhibitor Nephrotoxicity. Am J Kidney Dis. 2017; 69(5):e21-e22. DOI: 10.1053/j.ajkd.2017.02.003. View

Akilesh S, Suleiman H, Yu H, Stander M, Lavin P, Gbadegesin R . Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. J Clin Invest. 2011; 121(10):4127-37. PMC: 3195463. DOI: 10.1172/JCI46458. View

Korbet S . The treatment of primary focal segmental glomerulosclerosis. Ren Fail. 2000; 22(6):685-96. DOI: 10.1081/jdi-100101956. View

Schaldecker T, Kim S, Tarabanis C, Tian D, Hakroush S, Castonguay P . Inhibition of the TRPC5 ion channel protects the kidney filter. J Clin Invest. 2013; 123(12):5298-309. PMC: 3859394. DOI: 10.1172/JCI71165. View

Heerspink H, Andress D, Bakris G, Brennan J, Correa-Rotter R, Dey J . Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018; 20(6):1369-1376. PMC: 5969254. DOI: 10.1111/dom.13245. View

10.

Yu M, Ledeboer M, Daniels M, Malojcic G, Tibbitts T, Coeffet-Le Gal M . Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis Model. ACS Med Chem Lett. 2019; 10(11):1579-1585. PMC: 6862342. DOI: 10.1021/acsmedchemlett.9b00430. View

11.

Persson F, Lewis J, Lewis E, Rossing P, Hollenberg N, Parving H . Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care. 2010; 33(11):2304-9. PMC: 2963484. DOI: 10.2337/dc10-0833. View

12.

Greka A, Mundel P . Balancing calcium signals through TRPC5 and TRPC6 in podocytes. J Am Soc Nephrol. 2011; 22(11):1969-80. PMC: 3231779. DOI: 10.1681/ASN.2011040370. View

13.

Brown K, Campbell C, Roberts G . Precision medicine in kidney disease: the patient's view. Nat Rev Nephrol. 2020; 16(11):625-627. PMC: 7404073. DOI: 10.1038/s41581-020-0319-0. View

14.

Lambers Heerspink H, Oberbauer R, Perco P, Heinzel A, Heinze G, Mayer G . Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine. Nephrol Dial Transplant. 2015; 30 Suppl 4:iv105-112. DOI: 10.1093/ndt/gfv210. View

15.

Robins R, Baldwin C, Aoudjit L, Cote J, Gupta I, Takano T . Rac1 activation in podocytes induces the spectrum of nephrotic syndrome. Kidney Int. 2017; 92(2):349-364. DOI: 10.1016/j.kint.2017.03.010. View

16.

McGrogan A, Franssen C, de Vries C . The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2010; 26(2):414-30. DOI: 10.1093/ndt/gfq665. View

17.

Heerspink H, List J, Perkovic V . New clinical trial designs for establishing drug efficacy and safety in a precision medicine era. Diabetes Obes Metab. 2018; 20 Suppl 3:14-18. PMC: 6220936. DOI: 10.1111/dom.13417. View

18.

DAgati V, Kaskel F, Falk R . Focal segmental glomerulosclerosis. N Engl J Med. 2011; 365(25):2398-411. DOI: 10.1056/NEJMra1106556. View

19.

Gipson D, Gibson K, Gipson P, Watkins S, Moxey-Mims M . Therapeutic approach to FSGS in children. Pediatr Nephrol. 2006; 22(1):28-36. PMC: 1784542. DOI: 10.1007/s00467-006-0310-4. View

20.

Kitiyakara C, Kopp J, Eggers P . Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol. 2003; 23(2):172-82. DOI: 10.1053/snep.2003.50025. View